Citizen Capital invests in Phagos

Phagos raises €25M to deploy the world’s first approved phage-based veterinary treatments.

Because antibiotic resistance is one of the biggest threats of our century, and innovation must serve resilience, not just progress.

📊 Why it matters:
– One in three antibiotics used in livestock is now ineffective.
– Antimicrobial resistance already causes millions of deaths every year.
– Bacterial infections are among the top causes of mortality in animal farming and a major source of food system fragility.

Phagos’ technology offers a credible, scalable alternative — before the antibiotic era runs out of options.

💊 Founded in 2021, Phagos combines microbiology and AI to design ultra-precise phage therapies — natural bacterial predators used to cure infections.

It is the first EU company authorized to market personalized veterinary phage treatments, thanks to a unique regulatory milestone.

Its patented AI platform analyses the genomes of both phages and bacteria to predict interactions, enabling tailor-made treatments that evolve with bacterial resistance.

By tackling bacterial infections sustainably, Phagos contributes to:
– Reducing antibiotic use in agriculture
– Strengthening food resilience
– Paving the way for a new medical frontier

💰 This €25M Series A will fuel:
– Large-scale deployment of veterinary phage therapies
– Development of next-gen AI for phage characterization
– Global expansion across Europe, Asia and the Americas
– Team growth to bring these solutions to market

We’re happy to take part in this funding round, leaded by Capagro, Hoxton Ventures, CapHorn Invest and Demeter, to accelerate a revolution in sustainable health.

READ more